This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

The committee recommended the combo for patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations based on data from the MARIPOSA trial.

The company said the combo could help overcome resistance to EGFR inhibitors in patients whose tumors harbor the mutation.

The firm is submitting data showing that a one-time treatment with ST-920 led to a positive annualized estimated glomerular filtration rate slope.